Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Accumulated Expenses: 2009-2014

Historic Other Accumulated Expenses for Madrigal Pharmaceuticals (MDGL) over the last 6 years, with Dec 2014 value amounting to $6.2 million.

  • Madrigal Pharmaceuticals' Other Accumulated Expenses rose 1.06% to $5.0 million in Q3 2015 from the same period last year, while for Sep 2015 it was $5.0 million, marking a year-over-year increase of 1.06%. This contributed to the annual value of $6.2 million for FY2014, which is 8.03% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $6.2 million for FY2014, which was up 8.03% from $5.7 million recorded in FY2013.
  • In the past 5 years, Madrigal Pharmaceuticals' Other Accumulated Expenses registered a high of $6.2 million during FY2014, and its lowest value of $2.5 million during FY2012.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $5.4 million (2012), whereas its average is $4.9 million.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Other Accumulated Expenses fell by 6.88% in 2010 and then climbed by 11.60% in 2012.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Other Accumulated Expenses stood at $4.2 million in 2010, then rose by 9.54% to $4.6 million in 2011, then reached $2.5 million in 2012, then climbed by 11.60% to $5.1 million in 2012, then climbed by 11.53% to $5.7 million in 2013, then grew by 8.03% to $6.2 million in 2014.